
    
      Donors will undergo G-CSF mobilization of peripheral blood stem cells (PBSC) prior to
      undergoing two apheresis collections of hematopoietic progenitor cells (HPC,A) and one
      apheresis collection of therapeutic cell product of purified natural killer cells (TC-NK).

      The HPC products will be T-cell depleted (TCD) using the investigational CliniMACS device.
      CD34+ enrichment and CD45RA depletion will be utilized on sequential HPC grafts.

      Participants will undergo a preparative regimen of total lymphoid irradiation, fludarabine,
      cyclophosphamide, granulocyte colony stimulating factor (G-CSF), thiotepa, and melphalan.
      This is followed by infusions of donor cells that have been prepared using the CliniMACS
      system: HPC,A (CD34+ selected), HPC,A (CD45RA depleted), and TC-NK.
    
  